🎯📢Register for the new round of ECTS course DSPARK SPARK Webinar Series Fall 2026!
Do you want to explore the world of technological innovation and gain valuable know-how experts and successful entrepreneurs in the field from all around the world?
Register for the next webinar within the SPARK Global Webinar Series on "Protocol Development for Investigator-Sponsored Studies "!
This webinar will be held on Tuesday, December 9th, at 8AM CEST, and will be led by Dr. Lym Frumkin.
Speaker: Dr. Lyn Frumkin, biotechnology consultant
Dr. Lyn Frumkin is a consultant in biotechnology and life sciences investments. He has experience from Amgen and ICOS, where he led clinical teams and contributed to global development programs as well as regulatory strategies for the approval of therapeutics in the USA, Europe, and Japan.
He also served as a Consulting Professor at Stanford University and continues to act as an advisor to the SPARK program. As part of the Fulbright Specialist program, he provided expert consultations in translational medicine and global health in Taiwan in 2019.
Lyn earned a BS in Psychology with honors and a combined MD-PhD (Behavioral Medicine/Neuroscience) from the University of Washington. He completed his postgraduate clinical training in internal medicine at Stanford University, followed by specialization in neurology and infectious diseases/virology.
Key takeaways from the webinar
- Investigator-led clinical trials in academic settings can significantly advance drug development.
- Compared to industry- or government-sponsored studies, they often face limited operational and financial resources, including smaller participant numbers.
- These studies more frequently involve drug repurposing and are often conducted directly in patients rather than healthy volunteers. They also explore interventions in patients with more severe illness, comorbidities, or higher mortality risk.
- Despite their challenges, thorough protocol development can ensure scientific and ethical quality and help identify relevant outcomes that pave the way for larger, well-controlled trials.
